SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1996. CA Cancer J Clin. 1996; 46: 527.
  • 2
    Jemal A, Chu KC, Tarone RE. Recent trends in lung cancer mortality in the United States. J Natl Cancer Inst. 2001; 93: 277283.
  • 3
    Ginsberg RJ, Kris MG, Armstrong JM. Cancer of the lung. In: DevitaVT, HellmanS, RosenbergSA, editors. Cancer: Principles and practice of oncology, Philadelphia: JB Lippincott, 1993: 673722.
  • 4
    Bjorkqvist AM, Husgafvel-Pursiainen K, Anttila S, et al. DNA gains in 3q occur frequently in squamous cell carcinoma of the lung, but not in adenocarcinoma. Genes Chromosomes Cancer. 1998; 22: 7982.
  • 5
    Petersen S, Aninat-Meyer M, Schluns K, et al. Chromosomal alterations in the clonal evolution to the metastatic stage of squamous cell carcinomas of the lung. Br J Cancer. 2000; 82: 6573.
  • 6
    Pei J, Balsara BR, Li W, et al. Genomic imbalances in human lung adenocarcinomas and squamous cell carcinomas. Genes Chromosomes Cancer. 2001; 31: 282287.
  • 7
    Chujo M, Noguchi T, Miura T, et al. Comparative genomic hybridization analysis detected frequent overrepresentation of chromosome 3q in squamous cell carcinoma of the lung. Lung Cancer. 2002; 38: 2329.
  • 8
    Tai AL, Yan WS, Fang Y, Xie D, Sham JS, Guan XY. Recurrent chromosomal imbalances in nonsmall cell lung carcinoma: the association between 1q amplification and tumor recurrence. Cancer. 2004; 100: 19181927.
  • 9
    Guan XY, Fang Y, Sham JST, et al. Recurrent chromosome alterations in hepatocellular carcinoma detected by comparative genomic hybridization. Genes Chromosomes Cancer. 2000; 29: 110116.
  • 10
    ISCN. Guidelines for cancer cytogenetics. In: MitelmanF, editor. Supplement to International System for Human Cytogenetic Nomenclature. Basel: S. Karger, 1991.
  • 11
    Deng W, Tsao SW Guan XY, et al. Distinct profiles of critically short telomeres are a key determinant of different chromosome aberrations in immortalized human cells: whole-genome evidence from multiple cell lines. Oncogene. 2004; 23: 90909101.
  • 12
    Guan XY, Trent JM, Meltzer PS. Generation of band-specific painting probes from a single microdissected chromosome. Hum Mol Genet. 1993; 2: 11171121.
  • 13
    Xie D, Sham JS, Zeng WF, et al. Heterogenous expressions and associations of β-catenin, p16, E-cadherin, and C-myc in multistage colorectal carcinogenesis and progression. Int J Cancer. 2003; 107: 896902.
  • 14
    Petersen I, Bujard M, Petersen S, et al. Patterns of chromosomal imbalances in adenocarcinoma and squamous cell carcinoma of the lung. Cancer Res. 1997; 57: 23312335.
  • 15
    Brass N, Racz A, Heckel D, Remberger K, Sybrecht GW, Meese EU. Amplification of the genes BCHE and SLC2A2 in 40% of squamous cell carcinoma of the lung. Cancer Res. 1997; 57: 22902294.
  • 16
    Massion PP, Kuo WL, Stokoe D, et al. Genomic copy number analysis of non-small cell lung cancer using array comparative genomic hybridization: implications of the phosphatidylinositol 3-kinase pathway. Cancer Res. 2002; 62: 36363640.
  • 17
    Guan XY, Sham JS, Tang TC, Fang Y, Huo KK, Yang JM. Isolation of a novel candidate oncogene within a frequently amplified region at 3q26 in ovarian cancer. Cancer Res. 2001; 61: 38063809.
  • 18
    Barch MJ, Knutsen T, Spurbeck JL. The AGT cytogenetics laboratory manual, 3rd ed. New York: Lippincott-Raven, 1997.
  • 19
    Sibilia M, Wagner EF. Strain-dependent epithelial defects in mice lacking the EGF receptor. Science. 1995; 269: 23423824.
  • 20
    Threadgill DW, Dlugosz AA, Hansen LA, et al. Targeted disruption of mouse EGF receptor: effect of genetic background on mutant phenotype. Science. 1995; 269: 230234.
  • 21
    Sibilia M, Fleischmann A, Behrens A, et al. The EGF receptor provides an essential survival signal for SOS-dependent skin tumor development. Cell. 2000; 102: 211220.
  • 22
    Pai R, Soreghan B, Szabo IL, Pavelka M, Baatar D, Tarnawski AS. Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat Med. 2002; 8: 289293.
  • 23
    Sekine I, Takami S, Guang SG, et al. Role of epidermal growth factor receptor overexpression, K-ras point mutation and c-myc amplification in the carcinogenesis of non-small cell lung cancer. Oncol Rep. 1998; 5: 351354.
  • 24
    Reissmann PT, Koga H, Figlin RA, Holmes EC, Slamon DJ. Amplification and overexpression of the cyclin D1 and epidermal growth factor receptor genes in non-small-cell lung cancer. Lung Cancer Study Group. J Cancer Res Clin Oncol. 1999; 125: 6170.
  • 25
    Abdollahi A, Bao R, Hamilton TC. LOT1 is a growth suppressor gene down-regulated by the epidermal growth factor receptor ligands and encodes a nuclear zinc-finger protein. Oncogene. 1999; 18: 64776487.
  • 26
    Onn A, Correa AM, Gilcrease M, et al. Synchronous overexpression of epidermal growth factor receptor and HER2-neu protein is a predictor of poor outcome in patients with stage I non-small cell lung cancer. Clin Cancer Res. 2004; 10: 136143.
  • 27
    Swinson DE, Cox G, O'Byrne KJ. Coexpression of epidermal growth factor receptor with related factors is associated with a poor prognosis in non-small-cell lung cancer. Br J Cancer. 2004; 91: 13011307.
  • 28
    Alroy I, Yarden Y. The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions. FEBS Lett. 1997; 410: 8386.
  • 29
    Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer. 2002; 2: 489501.
  • 30
    Sithanandam G, Smith GT, Masuda A, Takahashi T, Anderson LM, Fornwald LW. Cell cycle activation in lung adenocarcinoma cells by the ErbB3/phosphatidylinositol 3-kinase/Akt pathway. Carcinogenesis. 2003; 24: 15811592.
  • 31
    Fan CS, Wong N, Leung SF, et al. Frequent c-myc and Int-2 overrepresentations in nasopharyngeal carcinoma. Hum Pathol. 2000; 31: 169178.
  • 32
    Seki A, Yoshinouchi M, Seki N, Kodama J, Miyagi Y, Kudo T. Detection of c-erbB-2 and FGF-3 (INT-2) gene amplification in epithelial ovarian cancer. Int J Oncol. 2000; 17: 103106.
  • 33
    Esteller M, Garcia A, Martinez i Palones JM, Cabero A, Reventos J. Detection of c-erbB-2/neu and fibroblast growth factor-3/INT-2 but not epidermal growth factor receptor gene amplification in endometrial cancer by differential polymerase chain reaction. Cancer. 1995; 75: 21392146.
  • 34
    Lidereau R, Callahan R, Dickson C, Peters G, Escot C, Ali IU. Amplification of the int-2 gene in primary human breast tumors. Oncogene Res. 1988; 2: 28529142.
  • 35
    Xu J, Tyan T, Cedrone E, Savaraj N, Wang N. Detection of 11q13 amplification as the origin of a homogeneously staining region in small cell lung cancer by chromosome microdissection. Genes Chromosomes Cancer. 1996; 17: 172178.
  • 36
    Moore R, Casey G, Brookes S, Dixon M, Peters G, Dickson C. Sequence, topography and protein coding potential of mouse int-2: a putative oncogene activated by mouse mammary tumour virus. EMBO J. 1986; 5: 919924.
  • 37
    Jakobovits A, Shackleford GM, Varmus HE, Martin GR. Two proto-oncogenes implicated in mammary carcinogenesis, int-1 and int-2, are independently regulated during mouse development. Proc Natl Acad Sci U S A. 1986; 83: 78067810.
  • 38
    Wilkinson DG, Bhatt S, McMahon AP. Expression pattern of the FGF-related proto-oncogene int-2 suggests multiple roles in fetal development. Development. 1989; 105: 131136.
  • 39
    Lee FS, Lane TF, Kuo A, Shackleford GM, Leder P. Insertional mutagenesis identifies a member of the Wnt gene family as a candidate oncogene in the mammary epithelium of int-2/Fgf-3 transgenic mice. Proc Natl Acad Sci U S A. 1995; 92: 22682272.
  • 40
    Miyoshi K, Rosner A, Nozawa M, et al. Activation of different Wnt/beta-catenin signaling components in mammary epithelium induces transdifferentiation and the formation of pilar tumors. Oncogene. 2002; 21: 55485556.
  • 41
    Lese CM, Rossie KM, Appel BN, et al. Visualization of INT2 and HST1 amplification in oral squamous cell carcinomas. Genes Chromosomes Cancer. 1995; 12: 288295.
  • 42
    Tsuda T, Tahara E, Kajiyama G, Sakamoto H, Terada M, Sugimura T. High incidence of coamplification of hst-1 and int-2 genes in human esophageal carcinomas. Cancer Res. 1989; 49: 55055508.
  • 43
    Kitagawa Y, Ueda M, Ando N, Shinozawa Y, Shimizu N, Abe O. Significance of int-2/hst-1 coamplification as a prognostic factor in patients with esophageal squamous carcinoma. Cancer Res. 1991; 51: 15041508.
  • 44
    Taguchi T, Cheng GZ, Bell DW, et al. Combined chromosome microdissection and comparative genomic hybridization detect multiple sites of amplification DNA in a human lung carcinoma cell line. Genes Chromosomes Cancer. 1997; 20: 208212.
  • 45
    Ooi A, Takehana T, Li X, et al. Protein overexpression and gene amplification of HER-2 and EGFR in colorectal cancers: an immunohistochemical and fluorescent in situ hybridization study. Mod Pathol. 2004; 17: 895904.